Inventiva Stock Falls 23.37% Over the Week
The stock settled at €3.985 on Friday, October 10, after starting the week at €5.05 on Monday, October 6. This contraction occurred progressively throughout the five sessions, with the stock losing ground each day. Trading volumes saw a notable increase mid-week, peaking at 937,309 shares on Wednesday, October 9, more than double the volumes recorded on previous days. This downward movement is part of a generally deteriorated market environment, but with a significantly greater magnitude. The SBF 120 and the CAC 40 respectively lost 1.75% and 1.72% over the same period, a correction about thirteen times less pronounced than that of Inventiva. Despite this weekly decline, the stock still shows a progression of 174.8% over one year and 44.12% over three months, indicating a long-term upward dynamic that remains present.
This week was marked by several announcements from the biopharmaceutical company, specializing in the development of oral therapies for the treatment of metabolic steatohepatitis (MASH). On Monday, October 7, Inventiva revealed that it will present four abstracts at the American Association for the Study of Liver Diseases congress, which will be held from November 7 to 11 in Washington. These presentations will focus on the comparison between digital pathology and traditional glass slide analysis in the context of the phase 3 NATiV3 study, as well as on preclinical data related to lanifibranor, its main drug candidate. The following day, the company organized an event in New York aimed at analysts and investors, providing a strategic update before the publication of phase 3 results expected in the second half of 2026. Furthermore, on Thursday, October 9, the Danish giant Novo Nordisk announced the acquisition of Akero Therapeutics for $5.2 billion, an operation that drew the sector's attention to the MASH market. Akero is developing efruxifermin, a phase 3 FGF21 analogue, positioning this company as a direct competitor to Inventiva in this therapeutic indication. This transaction follows other recent acquisitions in the field, notably Roche's purchase of 89bio in September for $3.5 billion, signaling a growing interest from major laboratories in this therapeutic class.
